A Multicenter Placebo-controlled Clinical Trial of Oral Metoclopramide in Diabetic Gastroparesis

  1. Theodore Hersh, MD
  1. Gastroenterology Section, Yale University School of Medicine 333 Cedar Street, New Haven, Connecticut Veterans Administration Medical Center West Haven, Connecticut
  2. Mashassuck Medical Center Suite 304, 1 Randall Square, Providence, Rhode Island
  3. Rhode Island Hospital, Ambulatory Patient Center 593 Eddy Street, Providence, Rhode Island
  4. Kansas University Medical Center 1 Rainbow Boulevard at 39th Street, Kansas City, Kansas
  5. Cabrini Medical Center 277 East 19th Street, New York, New York
  6. Kansas University Medical Center 419 19th Street, Philadelphia, Pennsylvania
  7. Wadsworth VA Hospital Wilshire and Sawtelle Boulevards, Los Angeles, California
  8. Wadsworth VA Hospital 3115 Webster Street, Suite 312, Oakland, California
  9. Wadsworth VA Hospital Gastroenterology Associates, 110 Francis Street, Boston, Massachusetts
  10. Department of Gastroenterology, Emory University Clinic 1365 Clifton Road, N.E., Atlanta, Georgia
  1. Address reprint requests to Richard W. McCallum, M.D., Gastroenterology Section, 92 LMP, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510.


40 patients with diabetic gastroparesis. Results of a 3-wk double-blind study indicate that metoclopramide at a dosage of one 10-mg tablet four times daily reduced nausea, vomiting, fullness, and early satiety and improved meal tolerance better than placebo. Statistically significant differences were noted for nausea and postprandial fullness. Mean gastric emptying assessed by radionuclide scintigraphy was significantly improved in the metoclopramide-treated group when compared with their baseline result. Metoclopramide is an effective agent for improving the upper gastrointestinal motor function in diabetic patients with gastroparesis.

| Table of Contents